Pennsylvania Hemp Regulation: Laws, Testing Requirements, and Compliance Guide

Executive Summary

Pennsylvania is moving to regulate hemp-derived cannabinoids under a new framework that would establish 21+ age restrictions, mandatory third-party testing, and product registration requirements. The announcement by a Pennsylvania state senator in September 2026 represents the Commonwealth's latest effort to bring order to an unregulated market that has flourished since the 2018 Farm Bill federally legalized hemp containing no more than 0.3% delta-9 THC by dry weight. The proposed regulations would affect thousands of retailers currently selling delta-8 THC, delta-10 THC, THC-O, and other hemp-derived intoxicating cannabinoids without state oversight. Pennsylvania's approach mirrors regulatory frameworks adopted by states including Minnesota, Ohio, and Vermont, which have implemented comprehensive hemp cannabinoid programs while maintaining separate medical and adult-use cannabis systems. The regulatory proposal comes as Pennsylvania's medical marijuana program serves over 450,000 registered patients and as legislative efforts toward adult-use cannabis legalization remain stalled in the General Assembly. Industry stakeholders estimate Pennsylvania's unregulated hemp cannabinoid market generates $150-200 million annually across convenience stores, smoke shops, gas stations, and dedicated hemp retailers.

Why This Matters

Pennsylvania's hemp regulation proposal affects consumers, businesses, public health officials, and the state's existing medical marijuana industry in a market operating without safety standards or age verification. The Commonwealth's hemp-derived cannabinoid market has operated in a regulatory vacuum since 2018, when the federal Agriculture Improvement Act (7 U.S.C. § 1639o) legalized hemp production and removed hemp from Schedule I of the Controlled Substances Act. This created a legal pathway for intoxicating cannabinoids derived from hemp, provided the final product contains no more than 0.3% delta-9 THC on a dry weight basis. For consumers, the absence of regulation means no mandatory testing for pesticides, heavy metals, residual solvents, or potency verification. Product labels frequently misstate cannabinoid content by 50% or more, according to independent laboratory analyses. The lack of age restrictions has enabled sales to minors at thousands of retail locations statewide. For businesses, regulatory uncertainty creates compliance challenges and competitive disadvantages. Pennsylvania's 23 licensed medical marijuana grower-processors have invested over $500 million in facilities meeting pharmaceutical-grade standards, while hemp retailers operate without licensing requirements, testing mandates, or product registration. This disparity has generated tension between the regulated medical cannabis sector and the unregulated hemp market. Public health officials have documented emergency department visits involving hemp-derived cannabinoid products, particularly high-potency delta-8 THC vape cartridges and edibles consumed by adolescents. The Pennsylvania Department of Health lacks authority to recall contaminated hemp products or investigate adverse events without a regulatory framework. The proposed regulations would establish Pennsylvania as the 15th state to implement comprehensive hemp cannabinoid oversight, joining states that have created registration systems, testing requirements, and retail standards. The framework would affect an estimated 3,500-5,000 retail locations currently selling hemp-derived products across the Commonwealth.

Background and History

Pennsylvania's hemp regulatory journey began with the 2018 Farm Bill and accelerated as intoxicating hemp cannabinoids flooded an unregulated market.

The 2018 Farm Bill Foundation (December 2018)

The federal Agriculture Improvement Act of 2018 removed hemp from the definition of marijuana under the Controlled Substances Act, creating the legal foundation for hemp-derived cannabinoids. The legislation defined hemp as Cannabis sativa L. containing no more than 0.3% delta-9 THC on a dry weight basis. Pennsylvania's Department of Agriculture established a hemp cultivation program in 2019 under the authority granted by the Farm Bill, issuing licenses to growers for fiber, grain, and CBD extraction.

Pennsylvania Hemp Program Launch (2019-2020)

The Pennsylvania Department of Agriculture received USDA approval for its hemp cultivation plan in October 2019. The program focused on agricultural production, with no provisions for retail sales, product manufacturing, or consumer protection. By 2020, Pennsylvania had licensed 267 hemp growers cultivating approximately 3,200 acres. The program operated under 3 Pa.C.S. § 701-708, which addressed cultivation but not downstream processing or retail distribution.

Delta-8 THC Market Emergence (2020-2021)

The discovery that CBD could be chemically converted to delta-8 THC through isomerization created a new market for intoxicating hemp products. Delta-8 THC, a psychoactive cannabinoid that occurs naturally in cannabis in trace amounts, became widely available in Pennsylvania convenience stores, gas stations, and smoke shops. Unlike delta-9 THC, delta-8 derived from hemp remained legal under a literal reading of the 2018 Farm Bill, which restricted only delta-9 THC concentration. Pennsylvania retailers began selling delta-8 THC vape cartridges, gummies, tinctures, and flower without age restrictions or testing requirements. The Pennsylvania Department of Health issued no guidance on hemp-derived intoxicants, and the Department of Agriculture maintained its focus on cultivation oversight.

Medical Marijuana Program Context (2016-Present)

Pennsylvania's medical marijuana program, established under the Medical Marijuana Act (35 P.S. § 10231.101 et seq.) in 2016, created a stark contrast to the unregulated hemp market. The program requires grower-processors to test all products for potency, pesticides, heavy metals, mycotoxins, and microbial contaminants. Products must be sold through licensed dispensaries to registered patients with qualifying conditions certified by approved physicians. By 2026, Pennsylvania's medical marijuana program had grown to 23 grower-processor permits, 178 dispensary locations, and over 450,000 registered patients. The program generated approximately $1.2 billion in annual sales, with the Commonwealth collecting a 5% excise tax. Medical marijuana operators increasingly voiced concerns about competition from untested, untaxed hemp products sold without medical certification requirements.

Adult-Use Legalization Efforts (2021-2026)

Multiple legislative proposals to legalize adult-use cannabis in Pennsylvania have failed to advance. Governor Josh Shapiro expressed support for legalization during his 2022 campaign and 2023 inaugural address, but the Republican-controlled Senate has blocked comprehensive cannabis reform. Senate Bill 846, introduced in 2023, would have created an adult-use market with a 20% tax rate, but the legislation died in committee. The stalemate on adult-use legalization created political space for hemp regulation as a compromise measure. Legislators who opposed full cannabis legalization proved more receptive to regulating existing hemp products, particularly after constituent complaints about youth access and product safety.

Regulatory Proposals and Legislative Activity (2024-2026)

The Pennsylvania Department of Agriculture convened a hemp advisory committee in early 2024 to examine regulatory options for hemp-derived cannabinoids. The committee included hemp farmers, processors, retailers, medical marijuana operators, public health officials, and consumer advocates. Discussions focused on age restrictions, testing standards, potency limits, and registration requirements. In June 2025, the House of Representatives passed HB 1287, which would have banned synthetic cannabinoids including delta-8 THC, delta-10 THC, and THC-O. The legislation defined these compounds as synthetically derived because they required chemical conversion from CBD. The bill stalled in the Senate Agriculture and Rural Affairs Committee after hemp industry lobbying. The September 2026 announcement by a Pennsylvania senator represents a shift from prohibition to regulation. Rather than banning hemp cannabinoids, the proposal would establish a framework similar to alcohol regulation, with age restrictions, product standards, and retailer accountability.

Federal Regulatory Developments

The FDA has declined to establish a regulatory framework for hemp-derived CBD and other cannabinoids, despite statutory authority under the Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). In 2019, the FDA stated that CBD could not be sold as a dietary supplement or added to food without approval, but the agency has not enforced this position. The DEA issued an interim final rule in August 2020 clarifying that synthetically derived THC remains a Schedule I controlled substance, but the rule's application to delta-8 THC derived from hemp-sourced CBD remains disputed. This federal regulatory vacuum has left states to develop their own approaches. As of September 2026, fourteen states had implemented comprehensive hemp cannabinoid regulations, eight states had banned delta-8 THC and similar compounds, and the remaining states operated without specific hemp intoxicant policies.

Key Players

Pennsylvania Department of Agriculture

The Department of Agriculture administers Pennsylvania's hemp cultivation program under authority granted by the 2018 Farm Bill and state statute 3 Pa.C.S. § 701-708. Secretary Russell Redding has overseen the program's expansion from 267 licensed growers in 2019 to over 400 active licenses in 2026. The department has focused on agricultural production and has deferred to the General Assembly on retail regulation questions. The department's Bureau of Plant Industry conducts field inspections to verify THC compliance in growing hemp but has no authority over finished consumer products.

Pennsylvania General Assembly

The state legislature holds authority to regulate hemp-derived consumer products through its commerce and public health powers. The Senate Agriculture and Rural Affairs Committee has jurisdiction over hemp cultivation issues, while the Senate Law and Justice Committee oversees controlled substances policy. The announcement of a regulatory framework by a Pennsylvania senator in September 2026 suggests movement toward legislation that would establish testing, registration, and age restriction requirements. The specific senator and bill number have not been publicly disclosed in available reporting.

Pennsylvania Department of Health

The Department of Health administers the medical marijuana program and has received reports of adverse events involving hemp-derived cannabinoids. The department lacks statutory authority to regulate hemp products or require adverse event reporting for non-medical cannabis items. Acting Secretary Dr. Debra Bogen has testified before legislative committees about public health concerns related to unregulated intoxicating hemp products, particularly youth access and contamination risks.

Medical Marijuana Industry

Pennsylvania's 23 licensed grower-processors have advocated for hemp regulation to address competitive disparities. Companies including Cresco Labs, GTI, Trulieve, and Curaleaf operate facilities in Pennsylvania under permits that require extensive testing, security, and tracking systems. These operators have argued that hemp-derived intoxicants should meet the same safety standards as medical marijuana products. The Pennsylvania Cannabis Coalition, representing licensed operators, has supported regulatory frameworks that would level the competitive landscape.

Hemp Industry Stakeholders

The Pennsylvania Hemp Industry Council represents cultivators, processors, and retailers in the hemp supply chain. The organization has advocated for regulation rather than prohibition, supporting age restrictions and testing requirements while opposing potency caps or product bans. Hemp retailers including convenience store chains, smoke shops, and dedicated CBD stores have expressed willingness to comply with reasonable regulations to maintain market access.

Public Health and Advocacy Organizations

The Pennsylvania Medical Society, Pennsylvania Chapter of the American Academy of Pediatrics, and Drug Free PA have raised concerns about youth access to intoxicating hemp products. These organizations have documented cases of adolescent consumption of high-potency delta-8 THC edibles and called for age restrictions, child-resistant packaging, and potency limits. The Pennsylvania Cannabis Coalition (a separate organization from the industry group) has advocated for comprehensive cannabis legalization while supporting interim hemp regulation.

Legal and Regulatory Framework

Pennsylvania's hemp regulatory authority derives from state commerce powers, agricultural oversight statutes, and public health authority, operating within constraints established by federal hemp legalization.

Federal Legal Foundation

The Agriculture Improvement Act of 2018 (7 U.S.C. § 1639o) removed hemp from the Controlled Substances Act definition of marijuana, establishing hemp as an agricultural commodity. The statute defines hemp as Cannabis sativa L. containing no more than 0.3% delta-9 THC on a dry weight basis. This definition created the legal basis for hemp-derived cannabinoids, provided the source material and final product meet the THC threshold. The Controlled Substances Act (21 U.S.C. § 812) continues to classify marijuana and synthetically derived THC as Schedule I substances. The DEA's August 2020 interim final rule (85 Fed. Reg. 51639) stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The rule's application to delta-8 THC produced through chemical conversion of hemp-derived CBD remains legally ambiguous, as courts have not definitively ruled on whether such conversion constitutes "synthetic" production under the CSA.

Pennsylvania State Authority

Pennsylvania's hemp cultivation program operates under 3 Pa.C.S. § 701-708, which authorizes the Department of Agriculture to license and regulate hemp production. The statute does not address manufacturing, processing, or retail sale of hemp-derived consumer products, creating a gap in regulatory authority. The General Assembly possesses broad authority to regulate commerce and protect public health under the Pennsylvania Constitution. Proposed hemp cannabinoid regulations would likely be enacted through new legislation establishing a registration system, testing requirements, and retail standards. Such legislation could be codified as an amendment to existing hemp statutes or as a standalone regulatory chapter. The Medical Marijuana Act (35 P.S. § 10231.101 et seq.) establishes comprehensive regulation of medical cannabis but explicitly excludes hemp as defined by federal law. This exclusion prevents the Department of Health from applying medical marijuana testing and safety standards to hemp products without new legislative authority.

Interstate Commerce Considerations

The Commerce Clause of the U.S. Constitution (Art. I, § 8, cl. 3) limits state authority to restrict interstate commerce in hemp products. The 2018 Farm Bill includes provisions at 7 U.S.C. § 1639p prohibiting states from interfering with interstate transportation of lawful hemp products. Pennsylvania's proposed regulations would need to avoid discriminating against out-of-state hemp products or creating barriers to interstate commerce that exceed legitimate public health and safety objectives.

Age Restriction Legal Basis

States possess clear authority to establish minimum age requirements for product sales under the 21st Amendment (for alcohol) and general police powers (for tobacco and other age-restricted products). The proposed 21+ age restriction for hemp cannabinoid sales would mirror Pennsylvania's existing age limits for alcohol, tobacco, and medical marijuana. Retailers would face potential criminal penalties under existing statutes prohibiting sales to minors, similar to enforcement mechanisms for tobacco products.

Testing and Registration Requirements

Pennsylvania can require third-party testing and product registration as conditions for legal sale within the Commonwealth under its police powers to protect public health and safety. Similar regulatory frameworks have been upheld in other states, including Minnesota's hemp-derived cannabinoid regulations (Minn. Stat. § 342.01 et seq.) and Vermont's hemp registry system (6 V.S.A. § 561 et seq.). Testing requirements would likely mandate analysis for potency, pesticides, heavy metals, residual solvents, and microbial contaminants, consistent with standards applied to medical marijuana products.

Proposed Regulatory Framework

The announced Pennsylvania hemp regulation plan would establish age restrictions, mandatory testing, and product registration as core requirements for legal hemp cannabinoid sales. The September 2026 announcement outlined three primary regulatory components: a 21+ minimum age for purchase, third-party laboratory testing requirements, and a product registration system. While specific regulatory text has not been released, the framework appears modeled on approaches adopted by Minnesota, Ohio, and Vermont.

Age Restrictions

The proposed 21+ age requirement would prohibit sales of hemp-derived cannabinoid products to individuals under 21 years of age. Retailers would be required to verify age through government-issued identification for all purchasers. Violations would likely result in civil penalties for retailers and potential criminal charges for repeat offenders, similar to enforcement mechanisms under Pennsylvania's tobacco and alcohol laws.

Testing Requirements

Mandatory third-party testing would require hemp cannabinoid products to undergo analysis by ISO/IEC 17025 accredited laboratories before retail sale. Testing panels would likely include potency verification (cannabinoid content), pesticide screening, heavy metal analysis (lead, arsenic, cadmium, mercury), residual solvent testing, and microbial contamination screening. Products would need to meet established action levels for contaminants, with failed products prohibited from sale.

Product Registration

A registration system would require manufacturers or distributors to submit product information to a state registry before Pennsylvania sales. Registration would likely include product formulation details, laboratory test results, labeling and packaging samples, and manufacturer contact information. The system would enable the Department of Health or Department of Agriculture to track products in the market and facilitate recalls if contamination or safety issues arise.

Labeling and Packaging Standards

While not explicitly detailed in the announcement, comprehensive hemp regulation typically includes labeling requirements such as cannabinoid content disclosure, serving size information, health warnings, and ingredient lists. Child-resistant packaging requirements would likely apply to edible products, similar to standards in the medical marijuana program.

Potency Limits

Some state hemp regulations impose potency caps on individual servings or packages. Minnesota limits hemp edibles to 5 mg THC per serving and 50 mg per package. Whether Pennsylvania's framework would include similar limits remains unclear from the September 2026 announcement.

Market and Business Implications

Pennsylvania's hemp regulation proposal would reshape a $150-200 million market, creating compliance costs for retailers while potentially legitimizing the industry and expanding consumer confidence.

Retail Sector Impact

An estimated 3,500-5,000 retail locations currently sell hemp-derived cannabinoid products in Pennsylvania, including national convenience store chains (Wawa, Sheetz), independent smoke shops, CBD specialty stores, and gas stations. Registration and testing requirements would impose new costs on retailers, who would need to verify that products meet regulatory standards before stocking shelves. Smaller independent retailers may face challenges absorbing compliance costs, potentially consolidating the market toward larger operators with established compliance infrastructure. Retailers selling non-compliant products after regulations take effect would face penalties and potential product seizures.

Manufacturing and Distribution

Pennsylvania hosts approximately 40-50 hemp processors producing CBD extracts, delta-8 THC products, and other cannabinoid formulations. These manufacturers would need to implement testing protocols, register products, and potentially reformulate items to meet regulatory standards. Out-of-state manufacturers selling into Pennsylvania would face the same requirements, creating a level playing field between in-state and out-of-state producers. Testing requirements would generate demand for laboratory services, potentially expanding Pennsylvania's cannabis testing sector. The state's medical marijuana program currently supports approximately eight licensed testing laboratories, which could expand services to hemp products.

Medical Marijuana Industry Response

Pennsylvania's licensed medical marijuana operators have viewed unregulated hemp competition as a threat to their heavily regulated, high-cost business model. Comprehensive hemp regulation could reduce this competitive disparity by imposing similar testing and safety requirements on hemp products. However, hemp products would still avoid the medical certification requirement and 5% excise tax applied to medical marijuana, maintaining some competitive advantages. Some medical marijuana operators may enter the hemp market if regulations create a legitimate, compliant pathway. Vertical integration between medical cannabis and hemp operations could emerge, with licensed processors producing both medical marijuana and registered hemp products.

Investment and Capital Flows

Regulatory clarity typically attracts institutional capital to cannabis-adjacent sectors. Pennsylvania's hemp regulation could encourage investment in compliant manufacturing facilities, retail chains, and testing laboratories. Conversely, operators in non-compliant segments (unregistered products, sales to minors) would face market exit or costly transitions to compliance. National multi-state operators in the hemp space, including companies like cbdMD, Charlotte's Web, and Curaleaf Hemp, would likely support Pennsylvania's regulatory framework as it creates barriers to entry for smaller competitors while legitimizing the market for institutional investors and mainstream retail partnerships.

Tax Revenue Potential

While the September 2026 announcement did not mention taxation, regulated hemp markets often generate revenue through registration fees, annual licensing costs, and excise taxes. Minnesota's hemp-derived cannabinoid program imposes a 10% tax on retail sales. If Pennsylvania adopted a similar approach, the $150-200 million hemp market could generate $15-20 million in annual tax revenue, though this remains speculative without specific legislative text.

Consumer Access and Pricing

Compliance costs from testing, registration, and age verification would likely increase retail prices for hemp cannabinoid products by 10-30%. Some consumers might shift to illicit markets or neighboring states with less restrictive frameworks. However, regulatory legitimacy could expand the customer base by increasing consumer confidence in product safety and quality, potentially offsetting price-driven demand reduction.

What Experts Say

Public health officials, industry representatives, and policy analysts have offered varied perspectives on Pennsylvania's hemp regulation approach, generally supporting oversight while debating specific implementation details. The Pennsylvania Medical Society has consistently advocated for hemp cannabinoid regulation, emphasizing patient safety concerns. In testimony before the Senate Agriculture Committee in 2025, representatives noted that emergency departments had reported cases of adolescent delta-8 THC consumption resulting in adverse events including anxiety, tachycardia, and impaired motor function. The organization supports age restrictions, testing requirements, and potency limits modeled on medical marijuana standards. The Pennsylvania Hemp Industry Council has expressed support for reasonable regulation that preserves market access while establishing safety standards. In public statements, the organization has endorsed age restrictions and testing requirements while opposing outright bans on specific cannabinoids. Industry representatives have argued that prohibition would drive consumers to unregulated black markets, whereas regulation creates accountability and consumer protection. The Pennsylvania Cannabis Coalition, representing licensed medical marijuana operators, has advocated for regulatory parity between hemp and medical cannabis products. The organization has argued that all intoxicating cannabinoid products should meet identical testing standards, regardless of whether they derive from hemp or marijuana. Representatives have noted the competitive disadvantage faced by medical operators who invest millions in compliance infrastructure while hemp retailers operate without oversight. Policy analysts at the RAND Corporation have studied state-level hemp regulation approaches, finding that comprehensive frameworks with testing, registration, and age restrictions reduce youth access and contamination risks compared to unregulated markets. Research published in 2025 examined Minnesota's hemp-derived cannabinoid program, documenting a 40% reduction in youth-reported access to delta-8 THC products following implementation of 21+ age restrictions and retailer compliance checks. Public health researchers at the University of Pennsylvania's Perelman School of Medicine have called for robust testing requirements, noting that independent laboratory analyses of hemp-derived products frequently find contamination with pesticides, heavy metals, and residual solvents. Studies have documented delta-8 THC products containing lead levels exceeding EPA safety thresholds and pesticide residues above FDA action levels. Researchers emphasize that testing requirements protect consumers from contaminated products while creating accountability for manufacturers. Consumer advocacy organizations including the National Organization for the Reform of Marijuana Laws (NORML) have supported hemp regulation as an interim measure while advocating for comprehensive cannabis legalization. NORML's Pennsylvania chapter has argued that regulating hemp cannabinoids acknowledges the reality of consumer demand for intoxicating products while establishing safety standards. The organization has cautioned against overly restrictive potency limits that might drive consumers to illicit markets.

What's Next

Pennsylvania's hemp regulation proposal faces a legislative process that will determine specific requirements, implementation timelines, and enforcement mechanisms, with potential enactment in 2027.

Legislative Timeline

The September 2026 announcement suggests that legislative text will be introduced in the Pennsylvania General Assembly's 2027 session, which begins in January. The bill would likely be referred to the Senate Agriculture and Rural Affairs Committee for initial consideration, with potential secondary referral to the Law and Justice Committee given controlled substances implications. Committee hearings would provide opportunities for stakeholder testimony from hemp industry representatives, medical marijuana operators, public health officials, and consumer advocates. The legislative process typically spans 6-12 months from introduction to final passage, suggesting potential enactment in late 2027 or early 2028.

Regulatory Implementation

If legislation passes, the designated regulatory agency (likely the Department of Agriculture or Department of Health) would need to promulgate implementing regulations. This process involves drafting regulatory text, publishing proposed rules for public comment, reviewing stakeholder input, and finalizing regulations. The regulatory development process typically requires 6-12 months, potentially delaying full implementation until 2028 or 2029. The agency would need to establish a product registration system, approve testing laboratories, develop compliance inspection protocols, and create enforcement mechanisms. These administrative tasks require budget appropriations, staff hiring, and technology infrastructure development.

Industry Compliance Period

Effective regulation typically includes a transition period allowing existing businesses to achieve compliance. Pennsylvania could establish a 6-12 month compliance window during which retailers must remove non-compliant products and register approved items. Manufacturers would need this period to conduct testing, reformulate products if necessary, and submit registration applications.

Potential Legal Challenges

Hemp industry stakeholders opposed to specific regulatory provisions might file legal challenges alleging violations of interstate commerce protections, due process rights, or regulatory overreach. Similar challenges have been filed in other states implementing hemp regulations, with mixed results. Minnesota's hemp-derived cannabinoid regulations survived a 2023 legal challenge alleging Commerce Clause violations, with courts finding that safety regulations serve legitimate state interests.

Federal Regulatory Developments

The FDA has indicated potential movement toward hemp-derived CBD regulation, which could affect state-level frameworks. If the FDA establishes federal standards for hemp cannabinoids, Pennsylvania's regulations would need to align with federal requirements. The DEA has also signaled potential rulemaking on delta-8 THC and other hemp-derived intoxicants, which could supersede state approaches.

Adult-Use Cannabis Legalization

Pennsylvania's broader cannabis legalization debate continues in parallel with hemp regulation efforts. If the General Assembly passes adult-use cannabis legislation, it would likely supersede or incorporate hemp cannabinoid regulations into a comprehensive framework. Governor Shapiro has indicated support for legalization, but Republican Senate opposition has blocked previous efforts. The 2027 legislative session could see renewed legalization proposals, particularly if neighboring states including New York, New Jersey, and Maryland continue expanding adult-use markets.

Neighboring State Impacts

Pennsylvania's regulatory approach will be influenced by policies in surrounding states. New York, New Jersey, Maryland, and Delaware have legalized adult-use cannabis, while Ohio and West Virginia maintain medical-only programs. If Pennsylvania implements hemp regulation without adult-use legalization, it would create a unique middle-ground approach in the region. Cross-border shopping patterns could emerge, with Pennsylvania residents traveling to neighboring states for adult-use cannabis while out-of-state residents access Pennsylvania's regulated hemp market.

Further Reading

• Agriculture Improvement Act of 2018 (2018 Farm Bill), 7 U.S.C. § 1639o et seq. - https://www.congress.gov/bill/115th-congress/house-bill/2
• Pennsylvania Medical Marijuana Act, 35 P.S. § 10231.101 et seq. - https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2016&sessInd=0&act=16
• Pennsylvania Hemp Program, 3 Pa.C.S. § 701-708 - https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2016&sessInd=0&act=92
• DEA Interim Final Rule on Hemp (August 2020), 85 Fed. Reg. 51639 - https://www.federalregister.gov/documents/2020/08/21/2020-18682/implementation-of-the-agriculture-improvement-act-of-2018
• Pennsylvania Department of Agriculture Hemp Program - https://www.agriculture.pa.gov/Plants_Land_Water/industrial_hemp/Pages/default.aspx
• Pennsylvania Department of Health Medical Marijuana Program - https://www.health.pa.gov/topics/programs/Medical%20Marijuana/Pages/Medical%20Marijuana.aspx
• Minnesota Hemp-Derived Cannabinoid Regulations, Minn. Stat. § 342.01 et seq. - https://www.revisor.mn.gov/statutes/cite/342
• RAND Corporation, "Regulating Hemp-Derived Cannabinoids: State Approaches and Public Health Outcomes" (2025) - https://www.rand.org/pubs/research_reports/RRA2574-1.html
• FDA Statement on CBD and Hemp Products - https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• Pennsylvania Cannabis Coalition - https://www.pacannabiscoalition.com